Secukinumab
- Generic Name
- Secukinumab
- Brand Names
- Cosentyx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229022-83-6
- Unique Ingredient Identifier
- DLG4EML025
- Background
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Fo...
- Indication
Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy. In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.
...
- Associated Conditions
- Enthesitis Related Arthritis (ERA), Juvenile Idiopathic Arthritis (JIA), Juvenile psoriatic arthritis, Non-radiographic Axial Spondyloarthritis, Severe Plaque psoriasis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Plaque psoriasis
- Associated Therapies
- -
Brain Changes in Psoriasis After Secukinumab Treatment
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 23
- Registration Number
- NCT04717466
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 119
- Registration Number
- NCT04632927
- Locations
- 🇩🇪
Novartis Investigative Site, Ratingen, Germany
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Saakshi Khattri
- Target Recruit Count
- 20
- Registration Number
- NCT04571567
- Locations
- 🇺🇸
Mount Sinai West Dermatolgy, New York, New York, United States
Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Universita di Verona
- Target Recruit Count
- 70
- Registration Number
- NCT04469829
- Locations
- 🇮🇹
University of Verona, Verona, Italy
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 244
- Registration Number
- NCT04340076
- Locations
- 🇳🇱
Amphia Hospital, Breda, Netherlands
🇳🇱Radboudumc, Nijmegen, Netherlands
🇳🇱Máxima Medisch Centrum, Veldhoven, Netherlands
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 275
- Registration Number
- NCT04181762
- Locations
- 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸Kaiser Permanente Fontana, Fontana, California, United States
🇺🇸University of California LA, Los Angeles, California, United States
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 704
- Registration Number
- NCT04179175
- Locations
- 🇺🇸
Northwest Arkansas Center, Rogers, Arkansas, United States
🇺🇸MedDerm Associates, San Diego, California, United States
🇺🇸Southern California Skin and Laser, Whittier, California, United States
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 527
- Registration Number
- NCT04156620
- Locations
- 🇹🇷
Novartis Investigative Site, Istanbul, Turkey
A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT03866317
- Locations
- 🇺🇸
CURTIS (Massachusetts General Hospital), Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.